Moleculin Biotech, Inc. (MBRX) News
Track canonical SquawkNews coverage tagged to MBRX, Moleculin Biotech, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Moleculin Biotech: Preclinical Data Suggest Annamycin’s Pancreatic Activity Involves CD8+ T Cells
Moleculin Biotech announced preclinical data showing Annamycin’s antitumor activity in pancreatic cancer is partially mediated by CD8+ T cells.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K -
REGULATION | Sep 25, 2026, 05:14 PM UTC
L
Moleculin Biotech, Inc. (MBRX) Reports Preclinical Data Showing Immune-Mediated Annamycin Activity
Moleculin reported preclinical data at AACR showing Annamycin’s antitumor activity in pancreatic models is partly mediated by CD8+ T cells. The finding is preclinical and Annamycin is not in pancreatic cancer trials.Mate
NEWS | Sep 25, 2026, 05:08 PM UTC
L
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic ac
NEWS | Sep 25, 2026, 05:08 PM UTC
L
Moleculin Secures Mexican Patent for Lung-Targeted Liposomal Annamycin; ATM Sales and Warrant Price Adjusted
Moleculin secured a Mexican patent for its lung-targeted liposomal Annamycin and reported ATM share sales and a reduced warrant exercise price.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K -
REGULATION | Sep 23, 2026, 12:34 PM UTC
L
Moleculin Biotech, Inc. (MBRX) Secures Mexican Patent for Lung-Targeted Annamycin Until 2040
Moleculin Biotech obtained Mexican Patent No. 436849 covering its lung-targeted liposomal Annamycin, with protection through Nov. 23, 2040.Material DetailsContext by AI AnalystThis adds to Moleculin’s ongoing IP build wh
NEWS | Sep 23, 2026, 12:32 PM UTC
L
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial OpportunityHOUSTON, Sept. 23, 2026 (GLOBE NEWSWIR
NEWS | Sep 23, 2026, 12:32 PM UTC
L
MBRX - Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
MBRX - Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
NEWS | Sep 23, 2026, 12:25 PM UTC
H
Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday. Following the market opening Monday, the Dow traded up 0.50% to 51,940.52 while the NASDAQ climbed 0.82% to 26,740.27. T
LIVE | Sep 21, 2026, 01:41 PM UTC
L
Moleculin to present new Annamycin data at AACR and European meetings
Moleculin announced new Annamycin data to be presented at AACR and two European scientific meetings in September 2026.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 14, 2026This is an A
REGULATION | Sep 14, 2026, 08:04 PM UTC
L
HC Wainwright cuts Moleculin Biotech price target to $3
HC Wainwright & Co. cut its Moleculin Biotech price target to $3.00/share from $22.00/share.
EQUITY | Aug 28, 2026, 11:19 AM UTC
L
Moleculin CEO Walter Klemp to participate in Virtual Investor conference
Moleculin CEO Walter Klemp is scheduled to participate in the Virtual Investor “Why Now” on-demand conference.
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
MBRX CEO Walter Klemp to participate in Virtual Investor conference
Moleculin CEO Walter Klemp is scheduled to participate in the Virtual Investor “Why Now” on-demand conference.
EQUITY | Aug 27, 2026, 01:02 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
Moleculin Biotech reports Q2 2026 financial results
Moleculin Biotech (MBRX) reports its second quarter 2026 financial results and highlights continued advancement of its pivotal MIRACLE trial.
EARNINGS | Aug 14, 2026, 12:30 PM UTC
H
Moleculin Prices $9.3M Public Offering
Moleculin announces $9.3 million public offering
EQUITY | Jul 31, 2026, 02:12 PM UTC
H
MBRX: No Cardiotoxicity Found
MBRX reports no cardiotoxicity with annamycin
EQUITY | Jul 31, 2026, 12:10 PM UTC
L
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
EQUITY | Jul 31, 2026, 12:10 PM UTC
M
MBRX Files Form S-1
MBRX files Form S-1 for common stock
FX | Jul 29, 2026, 01:45 PM UTC
L
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial
Moleculin Biotech, Inc., (NASDAQ: MBRX ) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.
EQUITY | Jul 06, 2026, 12:47 PM UTC
L
Why is Moleculin Stock Falling Today?
Moleculin Biotech Inc. (NASDAQ: MBRX ) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did no
EQUITY | Jun 30, 2026, 06:00 PM UTC
L
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remis
Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MI
EQUITY | Jun 30, 2026, 12:34 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers
EQUITY | Jun 23, 2026, 05:09 PM UTC